ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura

European Journal of Internal Medicine

Volumn 39, Issue , 2017, Pages 79-83

  Mancini, Ilaria ^a   Ferrari, Barbara ^b   Valsecchi, Carla ^b   Pontiggia, Silvia ^b   Fornili, Marco ^a   Biganzoli, Elia ^a   Peyvandi, Flora ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

ADAMTS13 protein; Immune complexes; Relapse; Risk factors; Thrombotic thrombocytopenic purpura

Indexed keywords

BIOLOGICAL MARKER; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTIGEN ANTIBODY COMPLEX; AUTOANTIBODY;

ACUTE PHASE RESPONSE; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RECURRENCE RISK; RELAPSE; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; REGRESSION ANALYSIS;

ADAMTS13 PROTEIN; ADULT; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; BIOMARKERS; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REGRESSION ANALYSIS;

EID: 85007004786     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.11.003     Document Type: Article

References (22)

1. Tsai, H.M., Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 91 (2010), 1–19, 10.1007/s12185–009–0476-1.
2. Schaller, M., Studt, J.D., Voorberg, J., Kremer Hovinga, J.A., Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie 33 (2013), 121–130, 10.5482/HAMO-12-12-0023 [12–12-0023 [pii]].
3. Lotta, L.A., Valsecchi, C., Pontiggia, S., Mancini, I., Cannavo, A., Artoni, A., et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost 12 (2014), 329–336, 10.1111/jth.12494.
4. Ferrari, S., Palavra, K., Gruber, B., Kremer Hovinga, J.A., Knobl, P., Caron, C., et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica 99 (2014), 779–787, 10.3324/haematol.2013.094151 [haematol.2013.094151 [pii]].
5. Lachmann, P.J., Walport, M.J., Deficiency of the effector mechanisms of the immune response and autoimmunity. Ciba Found Symp 129 (1987), 149–171.
6. Schifferli, J.A., Taylor, R.P., Physiological and pathological aspects of circulating immune complexes. Kidney Int 35 (1989), 993–1003.
7. Voice, J.K., Lachmann, P.J., Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol 27 (1997), 2514–2523, 10.1002/eji.1830271008.
8. Shashidharamurthy, R., Hennigar, R.A., Fuchs, S., Palaniswami, P., Sherman, M., Selvaraj, P., Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors. Blood 111 (2008), 894–904, 10.1182/blood-2007-04-085944 [blood-2007-04-085944 [pii]].
9. Karsten, C.M., Kohl, J., The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217 (2012), 1067–1079, 10.1016/j.imbio.2012.07.015 [S0171-2985(12)00179-9 [pii]].
10. Zhan, H., Streiff, M.B., King, K.E., Segal, J.B., Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 50 (2010), 868–874, 10.1111/j.1537–2995.2009.02528.x [TRF2528 [pii]].
11. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158 (2012), 323–335.
12. Mancini, I., Valsecchi, C., Lotta, L.A., Deforche, L., Pontiggia, S., Bajetta, M., et al. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost 112 (2014), 297–303, 10.1160/TH13-08-0688 [13-08-0688 [pii]].
13. Peyvandi, F., Mannucci, P.M., Valsecchi, C., Pontiggia, S., Farina, C., Retzios, A.D., ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates. Am J Hematol 88 (2013), 895–898, 10.1002/ajh.23527.
14. Peyvandi, F., Lavoretano, S., Palla, R., Feys, H.B., Vanhoorelbeke, K., Battaglioli, T., et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93 (2008), 232–239, 10.3324/haematol.11739 [haematol.11739 [pii]].
15. Bettoni, G., Palla, R., Valsecchi, C., Consonni, D., Lotta, L.A., Trisolini, S.M., et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 10 (2012), 1556–1565, 10.1111/j.1538–7836.2012.04808.x.
16. Agresti, A., Coull, B.A., Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 52 (1998), 119–126.
17. Schemper, M., Smith, T.L., A note on quantifying follow-up in studies of failure time. Control Clin Trials 17 (1996), 343–346.
18. Kremer Hovinga, J.A., Vesely, S.K., Terrell, D.R., Lammle, B., George, J.N., Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115 (2010), 1500–1511, 10.1182/blood-2009-09-243790 [blood-2009-09-243790 [pii]].
19. Ferrari, S., Mudde, G.C., Rieger, M., Veyradier, A., Kremer Hovinga, J.A., Scheiflinger, F., IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 7 (2009), 1703–1710, 10.1111/j.1538–7836.2009.03568.x [JTH3568 [pii]].
20. Terrell, D.R., Williams, L.A., Vesely, S.K., Lammle, B., Hovinga, J.A., George, J.N., The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 3 (2005), 1432–1436, 10.1111/j.1538–7836.2005.01436.x [JTH1436 [pii]].
21. Miller, D.P., Kaye, J.A., Shea, K., Ziyadeh, N., Cali, C., Black, C., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 15 (2004), 208–215 [00001648-200403000-00014 [pii]].
22. Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142 (2008), 819–826, 10.1111/j.1365–2141.2008.07276.x [BJH7276 [pii]].